
EMBRACING FOREIGN ORGANS: MANAGING TRANSPLANT PATIENTS IN THE EMERGENCY DEPARTMENT

Rosny Daniel, MD



CASES

65-year-old man, h/o ESRD s/p renal transplant presents with decreased urine output

22-year-old woman, h/o toxin mediated liver failure s/p liver transplant presents with fever and fatigue


26-year-old transwoman, h/o ALL s/p stem cell transplant presents with fever, rash, and diarrhea

OBJECTIVES

Discuss	Review	Categorize	Formulate
Discuss the epidemiology of transplants in United States	Review basic principles of solid organ and hematopoietic transplant	Categorize common transplant complications	Formulate an initial approach to evaluation, work up, and treatment of transplant complications

REFERENCES AND HIGH YIELD FIGURES

TRANSPLANT TIMELINE






EPIDEMIOLOGY

- Kidney > Liver > Lung > Heart > Pancreas
- 245k living kidney transplant patients
- 100k living liver transplant patients
- 110k living hematopoietic cell transplant patients
- 230+ Transplant centers in the US

Transplants Performed by Organ




In 2023

*Other includes allograft transplants like face, hands, and abdominal wall.

Based on OPTN data as of September 15, 2024. Data subject to change based on future data submission or correction. Totals may be less than the sums due to patients included in multiple categories.

Current state of organ donation and transplantation: Transplant trends



About the dashboard


0

This dashboard can be used to explore transplant and donor trends and key statistics. This data visualization shows high-level data on transplants, deceased donors recovered, patients added to the waitlist and patients



Select region Select organ Select age group Adult (18 years and older) Kidney Southwest • • Select race/ethnicity Select status Select month (All) . Active December 0 2025 2024 2023 2022 2021 2020 2019 Year-to-date adult transplants in the southwestern US 4,000 nsplants

INDICATIONS FOR TRANSPLANTS



SIMPLIFIED REQUIREMENTS FOR TRANSPLANT PATIENTS



Medical adherence



Lifestyle modifications

Sobriety



Support system



Commitment to the process

TRANSPLANT COMPLICATIONS

Organ specific

Mechanical and anatomic issues

Rejection

Medication side effects

Infections

Contacting the transplant team

Acute <1 month

Intermediate 1-6 months

Chronic >6 months


TRANSPLANT HISTORY

- When was their transplant?
- Where is their transplant?
- Where was their transplant?
- Who did their transplant?
- Current medications?




MECHANICAL COMPLICATIONS

- Blood supply
- Organ specific function
- Denervation



NOMENCLATURE







MECHANICAL COMPLICATIONS: KIDNEY TRANSPLANTS

- Renal artery stenosis and thrombosis
 - 10% rate
- Peri-transplant hematoma
 - 2-3% rate
- Ureteral obstruction
 - 3-6%
- Lymphocele
 - 5-15%

MECHANICAL COMPLICATIONS: LIVER TRANSPLANTS

- Thrombosis and stenosis of the hepatic artery
 - 4-12% rate
- Biliary strictures anastamotic vs non anastamotic
 - 4-20% rate
- Biliary leaks and bilomas
 - 2-25% rate






Completed operation. Note suture lines on now-implanted hea

MECHANICAL COMPLICATIONS: HEART TRANSPLANTS

- Allograft vasculopathy
 - 30-70% of patients
- Denervation
 - Decreased vagal tone
 - Bradycardia (no atropine)
 - Decreased sensation
- Tachyarrhythmia
 - >20% of patients
 - Beware CCBs

MECHANICAL COMPLICATIONS: LUNG TRANSPLANTS


- Airway anastomosis
 - 30-70% rate
- Arterial/Venous stenosis and thrombosis
 - Rare but morbid
- Phrenic nerve dysfunction
 - 3-10% rate
- Pneumothorax, hemothorax, chylothorax



ANATOMIC COMPLICATIONS EXAM & IMAGING


Transplanted Kidney

- Usually heterotopic
- Bedside ultrasound
- Doppler ultrasound
- CT angiogram



Transplanted Liver


- Usually orthotopic
- Bedside ultrasound
- Doppler ultrasound
- CT angiogram
- MRCP
- ERCP



ANATOMIC COMPLICATIONS EXAM & IMAGING


Transplanted Heart

- Orthotopic
- Bedside ultrasound
- ECHO
- CT angiogram




Transplanted Lung

- Orthotopic
- Bedside ultrasound
- Chest X-ray
- CT angiogram




REJECTION




GRAFT VS HOST DISEASE

- T cells in the donor graft are activated
- Recognize the donor recipient as foreign and attack
- Skin symptoms rash, desquamation
- Liver injury pain, decreased function
- Gastrointestinal tract diarrhea, vomiting



EVALUATING FOR REJECTION

- CBC, CMP, Lipase
- INR
- CRP, ESR
- Troponin, BNP
- ULS, CT
- Biopsy




EVALUATING FOR REJECTION


Lung [47]	orthopnea, palpitations, near-syncope/syncope, peripheral edema, or gastrointestinal symptoms with right heart involvement - Chest pain is absent due to denervation during surgery - Dysrhythmias commonLung [47]- Shortness of breath and cough most common - Lung examination variable: clear lung fields, crackles, or decreased breath sounds - May demonstrate strider or

TREATMENT OF REJECTION

- Treat any organ failure emergencies
- Contact the transplant team
- High dose steroids
 - 500-1000 methylprednisolone
- Immunosuppressants
 - Mycophenolate, tacrolimus, sirolimus, thymoglobulin, or antibody-mediated treatment








MEDICATIONS

- Induction phase is 3-12 months
 - Typically, triple therapy
- Maintenance phase
 - Goal of 1-2 meds alone
- Many transplant services have their own pharmacist because of the complexity of these medications

		Induction (I)				
•	Basiliximab (Simulect)	Alemtuzumab (Campath)	Rituximab	Anti-Thymocyte Globulin (ATG)		
Class	Chimeric murine mAb	Humanized mAB	mAB	Polyclonal igG (from rabbit/horse)		
How It Works	IL-2 receptor antagonist .	Anti-CD52	Anti-CD20, B- cell depleting	Anti-thymocyte, T-cell depleting		
Timing	Non T-Cell depleting lasts 4-6 weeks	T cell depleting with 50% recovery at 3 yrs. B-cell recovery by 1 yr	lasts 12 mo (also used for AMR, DS)	lasts 3-6 months		
The Bad	Rare infusion reactions	Cytokine release syndrome (CRS); cytopenias	Infusion reactions	CRS, serum sickness, PTLD		

	I/M		Maintenance (M)				
•	Belatacept	Glucocorticoid	Tacrolimus (Prograf, Envarsus, Astagraf)	Cyclosporine (Neoral, Gengraf, Sandimmune)	Mycophenolic Acid (Cellcept, Myfortic)	Azathioprine	mTORi
Class	CTLA4-Ig	Steroids	Calcineurin inhibitor (CNI)	Calcineurin Inhibitor	Anti-metabolite (AM)	АМ	mTORi
How It Works	Binds CD80/86 receptor on APC and blocks interaction with CD28 (co-stim)	Inhibits cytokine production	Binds FKBP, inhibits nuclear translocation of nuclear factor of activated T- cells (NFAT)	Binds cyclophilin and inhibits nuclear translocation of NFAT	Reversible inhibitor of IMPDH and blocks de novo purine synthesis	Disrupts salvage and de-novo purine synthesis .	Arrests ce cycle in G1-S phas
Timing	l: dosed 10 mg/kg POD 0,4 week 2,4,8,12 M: 5 mg/kg monthly	I: Dosed with IV methylpred M: PO prednisone 5 mg daily	t ½ 9-18 hr, trough check 10-12 hours	t ½ Neoral/Gengraf: 5-18 hr t ½ 10-27 hours	t ½ Cellcept: 18 hr Myfortic: 15 hr Troughs not useful	t ½ 5 hr TPMT involved in metabolism	t ½ Sirolimus 62 hr Everolimu 30 hr
The Bad	PML; PTLD (recipient must be EBV lgG+); cytopenias	HTN; Bone dz;, HLD; Cushings; Weight gain	Alopecia; tremors; neurotoxicity. acute and chronic nephrotox	HTN; HLD; DM; Hyperkalemia; Gingival hyperplasia; Hirsutism; Acute and chronic nephrotoxicity	Contraindicated in pregnancy; Gl upset, cytopenias	Hepatotoxic cytopenias (safe in pregnancy however)	Proteinur Oral ulcers; ILI cytopenia Need 4 hours between Siro and CsA

- Renal effects
- Metabolic syndrome
- Malignancy
- Bone, joint, and tendon disease
- Med med interactions
 - CCBs, Amiodarone, Statins
 - Macrolides/Aminoglycosides
 - AEDs, phenobarbital, phenytoin, carbamazepine




Immunosuppressive agent	Mechanism of action	Adverse side effects
Cyclosporine	calcineurin inhibitor	Hypertension, renal insufficiency, hyperlipidemia, insulin resistance
Tacrolimus	calcineurin inhibitor	Hypertension, renal insufficiency, hyperlipidemia, insulin resistance
Mycophenolate	Inhibits IMPDH	Leukopenia, anemia, thrombocytopenia, GI side effects
Azathioprine	Inhibits adenosine/guanine production	Leukopenia, anemia, thrombocytopenia, pancreatitis
Sirolimus	mTOR inhibitor	Leukopenia, anemia, thrombocytopenia, Hepatic artery thrombosis, pulmonary toxicity
Prednisone	Suppresses cytokines, prostaglandins, leukotrienes	Hypertension, psychiatric disorders, hyperglycemia, hyperlipidemia, peptic ulcers, osteoporosis



NEW ONSET DIABETES AFTER TRANSPLANT (NODAT)

- Common, happens in 5-40% of patients
 - Kidney, liver, lung, up to 30%
 - Heart up to 40%
- Mostly related to rejection medications
 - Decreased secretion of insulin
 - Increased insulin resistance
- Similar mechanism to Type 2 DM
- Hyperglycemic emergencies in the early post transplant phase



INFECTIONS	Infection based on transplant period		
	Transplant period	Infection	
	Early: first month after transplantation Intermediate: 1-6 mo after transplantation	 Donor-derived: donor-derived bacteria (MRSA, VRE, tuberculosis), fungi (<i>Candida</i>), and parasite (toxoplasmosis, Chagas disease) Nosocomial/surgery-related: aspiration pneumonia, surgical site infection, urinary tract infection, superinfection of graft tissue, vascular access infection, <i>Clostridium difficile</i> colitis Most at risk for opportunistic infection: <i>Pneumocystis jirovecii, Histoplasma, Coccidioides, Cryptococcus</i>, hepatitis B/C, BK polyomavirus, Kaposi sarcoma, cytomegalovirus, tuberculosis, Epstein-Barr virus (EBV) Surgical site infections may arise in this period. Reactivation of dormant host infection (CMV, HZV, HSV, EBV) 	
	Late: >6 mo after transplantation	- Community-acquired infection: respiratory viruses, Pneumococcus, Legionella, Listeria, Influenza, EBV	

MRSA, Methicillin-resistant Staphylococcus aureus; VRE, Vancomycin-resistant Enterococci.



DIAGNOSING INFECTIONS

- All the basic labs you would already send
 - Attention to the neutrophil count
- CXR, Urinalysis, viral panel
- Blood and urine cultures
- Consider LP if any meningitic symptoms
- Extended viral testing CMV, HZV, HSV, EBV
- Stool testing
- Other causes of fever
 - Rejection, thrombus, meds, malignancy

TREATING INFECTIONS

- Late period are more likely to be typical infections
- Early/Intermediate period
 - Low threshold for broad spectrum antibiotics
 - Consider treatment for fungal/viral disease
 - Low threshold for admission
- Resuscitate as you already would





CONSULTATION

- Contact the transplant team early
- Discuss testing & imaging options
- Assist with medication decisions
- Help with disposition and follow up planning
- Low threshold to transfer if needed

IN SUMMARY

- Each transplanted organ brings unique anatomic and function specific complications, and you already know how to evaluate and treat most of these
- We tend to see acute, intermediate, and chronic phases of complications
- Maintain high suspicion for rejection and infection
- Symptoms may be muted because of anatomic, immunologic, and medication related issues
- Test broadly and consult early, especially if you are worried
- Transplant meds can cause renal, metabolic, malignancy, soft tissue, and med med interactions

CASES

65-year-old man, h/o ESRD s/p renal transplant presents with decreased urine output

22-year-old woman, h/o toxin mediated liver failure s/p liver transplant presents with fever and fatigue

26-year-old transwoman, h/o ALL s/p stem cell transplant presents with fever, rash, and diarrhea



THANK YOU & REFERENCES

